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Editor,
We read with great interest the article by László et al.1 on
the effects of goal-directed crystalloid vs. hydroxyethyl
starch (HES) fluid therapy on microcirculation during free
flap surgery. In a randomised clinical trial, the authors
compared the effect of crystalloids with HES on macro-
haemodynamics and microcirculatory effects, in patients
undergoing maxillofacial tumour resection and free flap
reconstruction, through the use of a multimodal, individu-
alised, approach-based algorithm that was applied to guide
haemodynamic support. Recorded endpoints included
microcirculatory perfusion as determined by laser-Doppler
flowmetry and the amount of crystalloids or HES infused
to achieve a predefined haemodynamic goal. The results
did not show any difference in microcirculatory perfusion
between patients assigned to crystalloids or HES, and a
greater amount of crystalloids (1.5 times higher total fluid
volume compared with patients treated with HES) was
needed to maintain the predefined haemodynamic goal.
We would like address to some issues related to this study.
First, because of concerns related to HES treatment,
raised since 2013, including an increased mortality and
kidney injury in ICU patients, the indication for HES
usage has been limited to volume replacement therapy
after acute blood loss.2 Moreover, after a trial on HES
safety that started in October 2017, the European Med-
icines Agency has published more restrictive rules for the
use of HES in clinical practice, including a controlled
access programme with the obligation for hospitals to be
accredited, healthcare professionals to be trained on the
safe use of HES solutions and for there to be warnings on
the packaging. The European Commission confirmed
these restrictions and took a European Union-wide le-
gally binding decision on 17 July 2018. Given this highly
disputed safety profile, we were wondering whether the
authors had considered the selected endpoints to be
adequate to balance out the possible risk for the recruited
patients.3
Second, in peri-operative fluid management, colloid use
in a ‘close loop system’ relates to the need for smaller
fluid volumes but is not associated with lower postopera-
tive complications when compared with crystalloids.4 We
wonder whether the ‘smaller volumes’ of HES compared
with crystalloids needed to achieve a predefined target
with the goal-directed fluid therapy, as reported in the
study, relate to a clinical benefit?
Third, given the controversies on potential harm it has
been claimed that HES use ‘[. . .] can only be justified
when clinically relevant benefits and safety are estab-
lished in trials designed and powered to evaluate both
outcomes. The absence of harm is insufficient’.3,5
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Editor,
We would like to thank Giordano et al.1 for their com-
ments concerning our recently published trial on the
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usage of colloid fluid therapy on microcirculation during
free flap surgery.2 They are raising three main issues.
The first is considering the safety of hydroxyethyl starch
(HES) in critically ill patients, especially taking into
consideration the European Commission’s rules and
restrictions on HES usage, issued on 17 July 2018.3
Our study protocol was designed, and the trial started
with the recruitment of patients, years before this regu-
lation came into effect. Also, we feel that the decision to
erase HES from clinical practice was not supported by
very strong evidence as this decision was based on the
results of clinical trials that did not apply adequate
haemodynamic monitoring and the fluid administration
was based on clinicians’ intuition or on inadequate indi-
ces.4–6 These trials have an important message: if the
current approach in fluid management is used, then
normovolaemic patients will be treated with cristalloids
or HES, and complications are inevitable. In other words,
it may be that it is not the HES, but our current clinical
practice that is responsible for the harmful effects of HES
observed in these trials. In our study, in contrast to these
large trials, we implemented the concept of detailed,
multimodal and individualised, haemodynamic monitor-
ing, to maximise the likelihood that only those patients
who were most probably hypovolaemic would treated
with fluids.1
The second question raised by Giordano et al. is whether
smaller volumes of colloids have any plausible clinical
benefit. Although it was not the aim of our study, our data
support the theory of Starling’s three-compartment mod-
el and provided additional information that using colloids
may have the benefit of reaching haemodynamic stability
two to three times faster compared with crystalloids. This
difference could potentially be important during fluid
resuscitation. This issue has to be investigated further.
The third issue raised by Giordano et al. relates to the use
of HES that ‘[. . .] can only be justified when clinically
relevant benefits and safety are established in trials
designed and powered to evaluate both outcomes’.3,7
Our study was not designed to address safety issues,
but to question a specific problem – the effect of differ-
ent fluids on microcirculation.
Finally, based on the comments depicted above, the
colloid vs. crystalloid debate including the effects of
HES is far from being closed. It is our strong belief that
precision-medicine and personalised-medicine should
take over the current ‘intuition-based’ approach to pro-
vide the best and safest treatment for the high-
risk patient.
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Editor,
I would like to congratulate László et al.1 for their well
performed comparison of crystalloid and colloid fluid for
goal-directed volume therapy during free flap surgery
that was recently published in the European Journal of
Anaesthesiology. Most evaluations of goal-directed fluid
therapy have used colloids but some studies, and many
clinicians, have turned to crystalloids. Therefore, Lás-
zló’s study is pertinent to the current practice of anaes-
thesia. However, I still have difficulties in understanding
why crystalloids are used for this purpose.
The reason underlying my difficulties in understanding is
that the acute rise in cardiac index (CI) induced by a
bolus infusion of crystalloid fluid is short-lived. When
crystalloid fluid is administered rapidly, within 3 to 5 min,
a redistribution phase will be very prominent. Almost half
of the induced plasma volume expansion will be lost
within 10 min (Fig. 1a). This is the case during general
anaesthesia and surgery except when there is a sudden
drop in arterial pressure, which transiently stops the
redistribution.2
The redistribution effect becomes smaller with the infu-
sion time, and is of negligible consequence for lengthy
infusions. Then, the rate of elimination is the key factor
determining plasma volume expansion, which has in fact
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